Last reviewed · How we verify
Intravenous Tislelizumab
Intravenous Tislelizumab is a PD-1 inhibitor Small molecule drug developed by BeOne Medicines. It is currently in Phase 3 development for Non-small cell lung cancer, Hepatocellular carcinoma, Gastric or gastroesophageal junction cancer. Also known as: BGB-A317, TEVIMBRA®, immunotherapy.
Tislelizumab is a monoclonal antibody that blocks PD-1 on T cells to enhance anti-tumor immune responses.
Tislelizumab is a monoclonal antibody that blocks PD-1 on T cells to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Hepatocellular carcinoma, Gastric or gastroesophageal junction cancer.
At a glance
| Generic name | Intravenous Tislelizumab |
|---|---|
| Also known as | BGB-A317, TEVIMBRA®, immunotherapy |
| Sponsor | BeOne Medicines |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the brake on T cell activation, allowing enhanced proliferation, activation, and cytotoxic function against cancer cells. The drug is designed with a modified Fc region to minimize binding to FcγR receptors, potentially reducing immune-related adverse events compared to other PD-1 inhibitors.
Approved indications
- Non-small cell lung cancer
- Hepatocellular carcinoma
- Gastric or gastroesophageal junction cancer
- Esophageal squamous cell carcinoma
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
Key clinical trials
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- Safety and Efficacy of NK510 to Treat NSCLC (EARLY_PHASE1)
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (PHASE1)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus (PHASE2)
- Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (PHASE1)
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Tislelizumab CI brief — competitive landscape report
- Intravenous Tislelizumab updates RSS · CI watch RSS
- BeOne Medicines portfolio CI
Frequently asked questions about Intravenous Tislelizumab
What is Intravenous Tislelizumab?
How does Intravenous Tislelizumab work?
What is Intravenous Tislelizumab used for?
Who makes Intravenous Tislelizumab?
Is Intravenous Tislelizumab also known as anything else?
What drug class is Intravenous Tislelizumab in?
What development phase is Intravenous Tislelizumab in?
What are the side effects of Intravenous Tislelizumab?
What does Intravenous Tislelizumab target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: BeOne Medicines — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Hepatocellular carcinoma
- Indication: Drugs for Gastric or gastroesophageal junction cancer
- Also known as: BGB-A317, TEVIMBRA®, immunotherapy
- Compare: Intravenous Tislelizumab vs similar drugs
- Pricing: Intravenous Tislelizumab cost, discount & access